New ATTUNE® Revision Knee System from DePuy Synthes Utilizes Proprietary Technologies to Address Broad Range of Complex Primary and Revision Procedures
Comprehensive revision system designed to provide stability in motion
NEW ORLEANS, March 6, 2018 /PRNewswire/ -- DePuy Synthes*, part of the Johnson & Johnson Medical Devices Companies**, today announced the US launch of the ATTUNE® Revision Knee System, to complement the ATTUNE Primary Knee System and provide surgeons with a comprehensive solution for knee replacement. The ATTUNE Revision Knee System is being introduced at the 2018 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in New Orleans, LA.
While knee replacement is widely recognized as one of the most common and successful surgical procedures, approximately five percent of patients will require a revision surgery 10 years after the initial procedure 1,2 for a variety of reasons. Revision surgeries can create complexities particularly in cases where large bone defects present reconstruction and fixation challenges. The ATTUNE Revision Knee System aims to address some of those challenges through improved kinematics, fixation and patient fit. With both fixed-bearing and rotating platform options, it is one of the most comprehensive revision knee systems available on the market today.
"The ATTUNE Revision Knee System provides the implant options I need to treat a variety of patient anatomies including more metaphyseal sleeve sizes, offset adaptors, stems and fixation choices," said Dr. Douglas Dennis***, Orthopaedic Surgeon, Denver, CO. "The ATTUNE Revision Knee System incorporates the advantages of the ATTUNE Primary Knee System such as AOX™ Polyethylene, enhanced locking mechanisms and improved kinematics via the ATTUNE GRADIUS™ Curve condylar geometry."
In a large, multi-center study, the ATTUNE Primary Knee System demonstrated improved outcomes across a broad range of Patient Reported Outcome Measures (PROMs) compared to certain existing knee brands at one-year minimum follow-up.3 The same technologies that helped deliver these outcomes are also incorporated in the ATTUNE Revision Knee System, helping to address overall patient satisfaction.
"The ATTUNE Revision Knee System introduces a new chapter in the ATTUNE Knee story," said Rajit Kamal, Vice President and Global Platform Leader, Knees, DePuy Synthes. "With six years of successful clinical history and more than 575,000 ATTUNE Primary Knees implanted worldwide, the new ATTUNE Revision Knee System allows us to bring proprietary technologies of the ATTUNE Knee System to more patients around the world."
The ATTUNE Revision Knee System is designed to work in harmony with the patient's anatomy to deliver stability in motion during activities such as stair ascent or descent, walking uphill or downhill or getting up from a chair through:
- ATTUNE GRADIUS Curve is designed to address the unnatural sliding of the femur on the tibia, to provide smooth motion and stability during everyday activities
- GLIDERIGHT™ Articulation is designed to enable the ATTUNE Knee design to more accurately replicate the normal patello-femoral kinematics of the native knee
The ATTUNE Revision Knee System is now available in the US. For more information, please click here.
About the Johnson & Johnson Medical Devices Companies
The Johnson & Johnson Medical Devices Companies** have been working to make surgery better for more than a century. With substantial breadth and depth in surgical and orthopaedic technologies and interventional solutions, we aspire to improve and enhance medical care for people worldwide. Together, we are working to shape the future of health through differentiated products and services.
About DePuy Synthes
DePuy Synthes, part of the Johnson & Johnson Medical Devices Companies, provides one of the most comprehensive orthopaedics portfolios in the world. DePuy Synthes solutions, in specialties including joint reconstruction, trauma, craniomaxillofacial, spinal surgery and sports medicine, are designed to advance patient care while delivering clinical and economic value to health care systems worldwide. For more information, visit www.depuysynthes.com.
*DePuy Synthes represents the products and services of DePuy Synthes, Inc. and its affiliates.
**The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopaedics, and cardiovascular businesses within Johnson & Johnson's Medical Devices segment.
***Dr. Douglas Dennis is a consultant to DePuy Synthes Joint Reconstruction.
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the launch of a new product, the ATTUNE® Revision Knee System. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of DePuy Synthes and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; product efficacy or safety concerns resulting in product recalls or regulatory action; manufacturing difficulties and delays; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2017, including under the captions "Item 1A. Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements," and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither the Johnson & Johnson Medical Devices Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
1M. Khan, K. Osman, G. Green, F. S. Haddah (2016). The epidemiology of failure in total knee arthroplasty. The Bone & Joint Journal, 98-B (1 Suppl A), 105-12.
2Sharkey, Peter F., et al. "Why are total knee arthroplasties failing today – has anything changed after 10 years?" The Journal of Arthroplasty 29.9 (2014) 1774-1778.
3Hamilton W.G., Brenkel, I., Clatworthy, M., Dwyer, K., Himden, S., Lesko, J., Kantor, S.: Early Outcomes with a New Primary TKA System vs. Contemporary TKA: Interim Results of Two Worldwide, Multi-Center Prospective Studies. AAOS, San Diego, California, March 14-18, 2017, Poster 106. Other implants tested: SIGMA Knee (DePuy), NexGen® (Zimmer), Triathlon® (Stryker).
© DePuy Synthes 2018. All rights reserved.
DSUS/JRC/0218/2584
SOURCE DePuy Synthes
Share this article